7月17日，派格生物医药-B盘中下跌8.04%，报6.2港元，成交额4767.38万港元。公司此前因与纳斯达克上市公司Rani Therapeutics签署谅解备忘录，股价于7月10日大涨约29%后持续波动，本次下跌系前期催化效应消退后获利盘持续兑现。该谅解备忘录仍处于早期筛选阶段，距实质性临床推进及商业化落地仍有较长路径，市场对短期兑现预期进一步降温。
同日生物科技板块整体承压，康方生物跌9.68%，三生制药跌9.21%，科伦博泰生物跌4.38%，信达生物跌3.77%，百济神州跌2.73%，板块联动效应加剧个股抛压。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.